GlycoMimetics (GLYC) Competitors $0.26 +0.01 (+4.11%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.26 0.00 (-0.77%) As of 04/25/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GLYC vs. ANRO, RENB, ZIVO, MGX, IKNA, PYXS, KRON, GANX, ONCY, and VRCAShould you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include Alto Neuroscience (ANRO), Renovaro (RENB), ZIVO Bioscience (ZIVO), Metagenomi (MGX), Ikena Oncology (IKNA), Pyxis Oncology (PYXS), Kronos Bio (KRON), Gain Therapeutics (GANX), Oncolytics Biotech (ONCY), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical products" industry. GlycoMimetics vs. Alto Neuroscience Renovaro ZIVO Bioscience Metagenomi Ikena Oncology Pyxis Oncology Kronos Bio Gain Therapeutics Oncolytics Biotech Verrica Pharmaceuticals GlycoMimetics (NASDAQ:GLYC) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, community ranking, dividends, earnings, profitability, valuation and institutional ownership. Is GLYC or ANRO more profitable? Alto Neuroscience's return on equity of -49.28% beat GlycoMimetics' return on equity.Company Net Margins Return on Equity Return on Assets GlycoMimeticsN/A -230.74% -177.39% Alto Neuroscience N/A -49.28%-33.52% Does the MarketBeat Community believe in GLYC or ANRO? GlycoMimetics received 301 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 84.21% of users gave Alto Neuroscience an outperform vote while only 57.85% of users gave GlycoMimetics an outperform vote. CompanyUnderperformOutperformGlycoMimeticsOutperform Votes31757.85% Underperform Votes23142.15% Alto NeuroscienceOutperform Votes1684.21% Underperform Votes315.79% Which has better valuation & earnings, GLYC or ANRO? Alto Neuroscience has lower revenue, but higher earnings than GlycoMimetics. Alto Neuroscience is trading at a lower price-to-earnings ratio than GlycoMimetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlycoMimetics$10K1,683.82-$37.88M-$0.59-0.44Alto NeuroscienceN/AN/A-$36.31M-$2.54-0.92 Do insiders and institutionals hold more shares of GLYC or ANRO? 75.2% of GlycoMimetics shares are held by institutional investors. 8.7% of GlycoMimetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer GLYC or ANRO? In the previous week, GlycoMimetics had 1 more articles in the media than Alto Neuroscience. MarketBeat recorded 3 mentions for GlycoMimetics and 2 mentions for Alto Neuroscience. GlycoMimetics' average media sentiment score of 0.93 beat Alto Neuroscience's score of 0.54 indicating that GlycoMimetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlycoMimetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, GLYC or ANRO? GlycoMimetics has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Comparatively, Alto Neuroscience has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Do analysts rate GLYC or ANRO? Alto Neuroscience has a consensus price target of $15.40, indicating a potential upside of 562.37%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, analysts plainly believe Alto Neuroscience is more favorable than GlycoMimetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlycoMimetics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 SummaryGlycoMimetics and Alto Neuroscience tied by winning 8 of the 16 factors compared between the two stocks. Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLYC vs. The Competition Export to ExcelMetricGlycoMimeticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.84M$6.70B$5.46B$7.82BDividend YieldN/A3.17%5.43%4.30%P/E Ratio-0.447.2022.3318.43Price / Sales1,683.82239.17391.12101.46Price / CashN/A65.8538.1834.62Price / Book3.266.306.684.19Net Income-$37.88M$142.95M$3.22B$248.05M7 Day Performance17.04%8.00%6.24%6.53%1 Month Performance6.92%-4.16%-2.81%-2.16%1 Year Performance-84.09%-2.77%16.46%4.71% GlycoMimetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLYCGlycoMimetics2.0832 of 5 stars$0.26+4.1%N/A-84.7%$16.84M$10,000.00-0.4450Analyst ForecastShort Interest ↓News CoverageANROAlto Neuroscience1.4143 of 5 stars$2.11-0.9%$15.40+629.9%-83.5%$57.12MN/A-0.83N/AGap UpRENBRenovaro0.6734 of 5 stars$0.36-4.9%N/A-78.0%$56.90MN/A-0.3920Positive NewsZIVOZIVO BioscienceN/A$15.00-11.8%N/AN/A$56.87M$15,850.00-3.0710Gap DownMGXMetagenomi1.3313 of 5 stars$1.52+2.7%$13.00+755.3%-74.2%$56.82M$52.30M-0.58236News CoverageIKNAIkena Oncology3.304 of 5 stars$1.17+6.4%$3.00+156.4%-9.2%$56.46M$659,000.00-0.9570Positive NewsPYXSPyxis Oncology1.1491 of 5 stars$0.92-4.6%$9.20+905.5%-75.3%$56.36M$16.15M-0.8960News CoverageKRONKronos Bio2.9135 of 5 stars$0.86+9.9%$1.63+89.5%-13.2%$52.29M$9.85M-0.60100Gap UpGANXGain Therapeutics2.8203 of 5 stars$1.87+11.1%$8.20+338.5%-38.3%$51.96M$50,000.00-1.7020News CoverageONCYOncolytics Biotech1.9525 of 5 stars$0.59-5.3%$4.33+634.5%-48.5%$50.99MN/A-2.1930News CoverageVRCAVerrica Pharmaceuticals3.8931 of 5 stars$0.55+14.2%$9.50+1,618.2%-92.6%$50.75M$7.57M-0.3040Positive News Related Companies and Tools Related Companies Alto Neuroscience Alternatives Renovaro Alternatives ZIVO Bioscience Alternatives Metagenomi Alternatives Ikena Oncology Alternatives Pyxis Oncology Alternatives Kronos Bio Alternatives Gain Therapeutics Alternatives Oncolytics Biotech Alternatives Verrica Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLYC) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GLYC Stock Free GLYC Stock Alerts